Fate Therapeutics Inc Investor Event - Corporate Call Transcript
Good day, and thank you for standing by. Welcome to the Fate Therapeutics Investor Call. (Operator Instructions) I would now like to hand the conference over to your first speaker today, Scott Wolchko. Please go ahead.
Thank you. Good afternoon. This is Scott Wolchko, President and CEO of Fate Therapeutics. Thank you all for joining us this afternoon to discuss our emerging cell-based cancer immunotherapy pipeline for solid tumors. We hope today's discussion will be informative, and will serve to highlight several areas of interest, including, number one, the unique features of our proprietary iPSC product platform and the distinct advantages it affords in developing multiplexed engineered cell therapies.
Number two, several novel mechanisms of attack that we are exploiting in the fight against solid tumors, including in concert with other immunotherapies that are used as standard of care. Number three, our emerging multiplexed engineered cell-based cancer immunotherapy
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |